Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Accured Expenses (2016 - 2026)

Champions Oncology has reported Change in Accured Expenses over the past 17 years, most recently at $1.2 million for Q1 2026.

  • Quarterly results put Change in Accured Expenses at $1.2 million for Q1 2026, up 3515.62% from a year ago — trailing twelve months through Jan 2026 was $1.1 million (up 761.96% YoY), and the annual figure for FY2025 was $395000.0, up 462.39%.
  • Change in Accured Expenses for Q1 2026 was $1.2 million at Champions Oncology, up from $388000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CSBR hit a ceiling of $1.2 million in Q1 2026 and a floor of -$755000.0 in Q3 2025.
  • Median Change in Accured Expenses over the past 5 years was $84500.0 (2024), compared with a mean of $68687.5.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 1098.41% in 2025 and later soared 3515.62% in 2026.
  • Champions Oncology's Change in Accured Expenses stood at -$287000.0 in 2022, then soared by 76.66% to -$67000.0 in 2023, then skyrocketed by 304.48% to $137000.0 in 2024, then soared by 183.21% to $388000.0 in 2025, then surged by 198.2% to $1.2 million in 2026.
  • The last three reported values for Change in Accured Expenses were $1.2 million (Q1 2026), $388000.0 (Q4 2025), and -$755000.0 (Q3 2025) per Business Quant data.